[1] 陈思丹.奥沙利铂联合贝伐单抗与卡培他滨方案治疗老年晚期胃
癌疗效及安全性评估[J].海南医学院学报,2014,20(4):490-493.
[2] 刘丽英,卢辉,王小倩.奥沙利铂联合替吉奥治疗老年晚期胃癌的
临床疗效观察[J]. 肿瘤基础与临床,2015,26(5):434-435.
[3] 王娟芳,刘贵生,高淑娟.伊立替康或奥沙利铂联合氟尿嘧啶治疗
老年晚期胃癌的临床疗效及安全性研究[J]. 现代消化及介入诊
疗,2016,21(4):597-599.
[4] 孟勇.卡培他滨与奥沙利铂联合贝伐单抗方案治疗老年晚期胃癌
疗效及安全性分析[J]. 海南医学院学报,2014,20(12):1707-
1710.
[5] 薛向生. 替吉奥联合奥沙利铂治疗老年晚期胃癌的疗效观察[J].
中国实用医刊,2015,42(8):30-31.
[6] 张瑜,倪婷婷,张汉群,等. 替吉奥联合奥沙利铂与替吉奥单药治
疗老年晚期胃癌的临床比较研究[J]. 肿瘤基础与临床,2015,26
(2):108-110.
[7] 张学苗,邵艳萍,薛惠.鸦胆子油乳注射液联合奥沙利铂与卡培他
滨治疗老年晚期胃癌的临床观察[J]. 中国药房,2015,26(27):
3769-3771.
[8] Luo Y, Yu H, Yang Y, et al. A flavonoid compound from
Chrysosplenium nudicaule inhibits growth and induces apoptosis
of the human stomach cancer cell line SGC- 7901 [J].
Pharm Biol, 2016,54(7):1133-1139.
[9] Terashima M, Ichikawa W, Ochiai A, et al. TOP2A,
GGH, and PECAM1 are associated with hematogenous,
lymph node, and peritoneal recurrence in stage Ⅱ/Ⅲ gastric
cancer patients enrolled in the ACTS- GC study [J].
Oncotarget, 2017,8(34):57574-57582.
[10] 韩明阳,聂洁伟,李媛媛.奥沙利铂联合替吉奥一线治疗老年晚期
胃癌的临床效果[J].临床医学,2016,36(7):47-48.
[11] Lee CK, Kim SS, Park S, et al. Depth of response is a
significant predictor for long- term outcome in advanced
gastric cancer patients treated with trastuzumab [J]. Oncotarget,
2017,8(19):31169-31179.